Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eiko LifesciencesBOM:540204 +2.02%70 Return-on-Tangible-Asset is 5.85% as of Jun. 2026, which is 114% above its 10-year median of 2.74. GuruFocus rates BOM:540204 with a GF Score™ of 70/100 and a GF Value™ of ₹77.31 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,618 Chemicals companies, Eiko Lifesciences ranks better than 70.58% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Eiko Lifesciences's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹52.3 Mil. Eiko Lifesciences's average total tangible assets for the quarter that ended in Jun. 2026 was ₹893.7 Mil. Therefore, Eiko Lifesciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 5.85%.
The historical rank and industry rank for Eiko Lifesciences's Return-on-Tangible-Asset or its related term are showing as below:
BOM:540204'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -4.51 Med: 2.74 Max: 6.66
Current: 6.66
During the past 13 years, Eiko Lifesciences's highest Return-on-Tangible-Asset was 6.66%. The lowest was -4.51%. And the median was 2.74%.
BOM:540204's Return-on-Tangible-Asset is ranked better than 70.58% of 1618
companies
in the Chemicals industry
Industry Median: 3.625
vs BOM:540204: 6.66
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Eiko Lifesciences Return-on-Tangible-Asset Related Terms
Eiko Lifesciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Eiko Lifesciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540204 vs LIN, SHW, ECL: Return-on-Tangible-Asset Comparison
For the Specialty Chemicals subindustry, Eiko Lifesciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiko Lifesciences Return-on-Tangible-Asset vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Eiko Lifesciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Eiko Lifesciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.85% mean?
Eiko Lifesciences (BOM:540204) has a Return-on-Tangible-Asset of 5.85% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eiko Lifesciences and its competitors. This is 114% above median its historical median of 2.74. According to the industry distribution chart, Eiko Lifesciences ranks #476 out of 1618 companies in the Chemicals industry, placing it in the top 29.4%.
Is Eiko Lifesciences' Return-on-Tangible-Asset too high?
Eiko Lifesciences' current Return-on-Tangible-Asset of 5.85% is 114% above median its 10-year median of 2.74. The Chemicals industry median Return-on-Tangible-Asset is 3.63. Eiko Lifesciences' value of 5.85% is 61.4% above this industry median. Based on the distribution chart, Eiko Lifesciences ranks #476 out of 1618 companies in the Chemicals industry, which is above the industry midpoint. Overall, Eiko Lifesciences has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eiko Lifesciences' Return-on-Tangible-Asset compare to LIN and SHW?
According to the Chemicals industry distribution chart, Eiko Lifesciences ranks #476 out of 1618 companies for Return-on-Tangible-Asset. This puts Eiko Lifesciences in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.63. Eiko Lifesciences' value of 5.85% is 61.4% above this benchmark. While the company's 10-year median is 2.74 vs. the industry median of 3.63, Eiko Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Chemicals company?
The median Return-on-Tangible-Asset among Chemicals companies is 3.63, based on 1,618 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiko Lifesciences's current Return-on-Tangible-Asset of 5.85% is 61.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eiko Lifesciences and its competitors. For the Chemicals industry, the median Return-on-Tangible-Asset is 3.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiko Lifesciences's current Return-on-Tangible-Asset is 5.85%, which is 114% above median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiko Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eiko Lifesciences (BOM:540204) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹77.31, compared to a current price of ₹47.99 — trading 37.9% below its estimated fair value. The current Return-on-Tangible-Asset is 5.85%, which is 114% above median its 10-year median of 2.74 and 61.4% above the Chemicals industry median of 3.63. Eiko Lifesciences' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Eiko Lifesciences (BOM:540204), the current Return-on-Tangible-Asset is 5.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eiko Lifesciences (BOM:540204) Overvalued in 2026?
Based on GuruFocus' analysis, Eiko Lifesciences stock appears to be undervalued.
The current stock price of ₹47.99 is trading 37.9% below its estimated GF Value™ of ₹77.31.
GuruFocus considers Eiko Lifesciences to be Significantly Undervalued.
Key valuation signals for BOM:540204:
Return-on-Tangible-Asset: 5.85% (114% above median its 10-year median of 2.74)
GF Value™: ₹77.31 vs. price of ₹47.99 (37.9% below fair value)
Industry Position: 61.4% above the Chemicals median (#476 of 1618)
No single metric tells the full story. See the BOM:540204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eiko Lifesciences Ltd is a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and pharma intermediates.. The company's segment includes Agrochemicals, Oleo Chemicals, Pharmaceuticals, Food Additives, clinical research, development, and Logistics. Geographically, the company generates the majority of its revenue from the Domestic market.
70GF Score
Get the complete analysis for BOM:540204
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540204 has been successfully added to your 
